top of page
The advanced science, research, and continued use of BENEV Exosomes has been steadily expanding. Voted as the #1 Best In Class Post Topical Solution, to date, there are more than 4,000 medical professional offices across the United States that integrate BENEV Exosomes to optimize treatment results.
Now that ExoCoBio, our proud partner and innovative leader in exosomes technology, has acquired BENEV, this synergistic merging of two companies will effectively boost the commercialization of exosome technology around the world.
IT'S OFFICIAL ...
The ExoCoBio x BENEV merger brings two leading companies together to allow for further innovation and global impact and to unite our Global Aesthetic Partners. ExoCoBio Inc. a global leader who specializes in Next-Generation exosome-based regenerative aesthetics, regenerative medicine, & immunotherapy has now merged with BENEV Company Inc, a FDA-registered Pharmaceutical, Cosmeceutical, and Medical Device company, founded in Orange County, California that serves the global medical aesthetic market with scientifically advanced, results-driven aesthetic solutions, medical devices, and nutraceuticals that optimize skin health. Now that ExoCoBio, our proud partner and innovative leader in exosomes technology, has acquired BENEV, this synergistic merging of two companies will effectively boost the commercialization of exosome technology around the world
LEADING AESTHETICS INTO THE FUTURE
ExoCoBio will continues to support BENEV's ongoing business ventures, including its medical device and PDO Thread Businesses
We could not be more thrilled to expand this strategic partnership even further and change the aesthetic industry forever!
“We are very pleased with this important acquisition, which will contribute to the fast growth and business expansion of ExoCoBio. BENEV is the perfect complement to our mission to bridge exosome science to clinical application to further elevate exosome technology as a mega-trend in the market.”
– Byong Cho
CEO and CTO of ExoCoBio
“We have been on a journey together as a strategic and financial partner for the last six years since the U.S. launch of Exosomes Regenerative Complex. With this acquisition, we are confident that our expertise, standing in the industry and the brand, paired with ExoCoBio’s science, technology, funding, and pipeline products will generate a strong synergy for our strategic growth in the global medical aesthetic market.”
– Ethan Min
CEO of BENEV
bottom of page